Marksans Pharma strengthens European presence with €7.5 million QliniQ acquisition - CNBC TV18
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
agilon health management, inc. (the borrower) and related entities filed a Third Amendment to their credit agreement dated February 12, 2026. The amendment is between the borrower, Agilon Health Intermediate Holdings, Inc., agilon health, inc. (parent), subsidiary guarantors, the lenders and issuers after amendment-related repayment and termination, and JPMorgan Chase Bank, N.A. as administrative agent.
The filing states the borrower intends to prepay the loans and terminate revolving credit commitments for a non-consenting lender under the credit agreement’s Section 11.1(d). The amendment also updates exhibits and schedules, including Exhibit W and Schedule I.
Filed under
Powered by Tentt
Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marksans Pharma→QliniQ
Jun 1, 2026
Frazier Healthcare Partners→Altruix
May 31, 2026
Signos
May 31, 2026
Sterling Bay→Pacific Center
May 29, 2026